RxDoctor Payments DataLook up a doctor →

Summer Allen, MD

Hospitalist · Gulfport, MSNPI 1730491036

Payments from drug & device makers

$52,955in general payments, 2019–2025

Across 757 payments — averaging $69.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$21K
  • Intuitive Surgical$7K
  • Veran Medical Technologies, Inc.$6K
  • Johnson & Johnson$5K
  • GSK$3K
  • AstraZeneca$2K
  • plus $9K from 47 others

What the payments were for

  • Consulting fees$16,53531%
  • Speaking & faculty fees$10,75020%
  • Travel & lodging$8,67516%
  • Food & beverage$14,07127%
  • Education$2,9256%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,955 in reported general payments places this provider in the 95th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$162,307
Medicare patients
560
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter504$376,488
Dupixent PenDupilumab35$128,142
Breztri AerosphereBudesonide/Glycopyr/Formoterol162$114,582
Ambrisentan12$41,325
SymbicortBudesonide/Formoterol Fumarate25$11,154
Albuterol Sulfate HfaAlbuterol Sulfate310$10,449
Breo ElliptaFluticasone/Vilanterol15$5,082
Montelukast Sodium641$3,057
Ventolin HfaAlbuterol Sulfate55$3,023
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,509
Roflumilast24$1,487
SynthroidLevothyroxine Sodium16$1,099
Fluticasone Propionate39$507
Prednisone154$327
Doxycycline Hyclate34$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,691$381,570519 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,883$125,737187 claims
AbbVieSynthroid$12$1,09916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →